我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

DCF (DOC+CDDP+5-FU) Therapy Led to Curative Resection in a Patient with Advanced Esophageal Carcinoma after the Failure of CF Therapy

Kazuma Kobayashi, Shun Yamaguchi, Takuro Fujita, Takahiro Ikeda, Ayaka Ishii, Shunsuke Murakami, Kengo Kanetaka, Fumihiko Fujita, Kosho Yamanouchi, Naomi Hayashida, Chika Sakimura, Sayaka Kuba, Fusako Kawakami1, Taiiichiro Kosaka1, Amane Kitasato1, Masaaki Hidaka, Akihiko Soyama, Shinichiro Ono, Yusuke Inoue, Shinichiro Kobayashi, Tomonori Tanaka, Na

In Japan, two courses of CF therapy followed by surgery are accepted as a standard treatment for stage II/III oesophageal cancer according to the result of the JCOG9907 trial. However, some cases experience insufficient anti-tumour effects with CF therapy. We experienced a case with oesophageal cancer that underwent curative resection and DCF therapy after the failure of CF therapy. The patient was a 51-year-old male who visited our department due to heart burn, back pain, and weight loss since July 2014. He was diagnosed with stage III (T3N2M0) oesophageal carcinoma and started neo adjuvant CF therapy on September 19, 2014. After the first course of CF, a CT scan showed enlarged lymph node swelling and swallowing disturbance was worsened. We attempted to start DCF therapy on October 29, 2014. The feasibility of this therapy was high, with manageable grade 2 diarrhoea and a transient high fever. Swallowing disturbance further subsided during the course of treatment. After DCF treatment, a CT scan showed shrinkage of LN swelling, as well as the primary lesion. We performed videoassisted thoracoscopic oesophagectomy and 3-field LN dissection. Pathological findings showed a grade 2 histological therapeutic effects by neoadjuvant chemotherapy and down staging of the tumour to stage II (T2N2M0) was attained, which indicated curative resection was achieved. If there is a discrepancy in the anti-tumour effect between the primary lesion and LNs by neoadjuvant CF therapy for stage II/III oesophageal cancer, then conversion to DCF therapy might be one of the treatment choices.